-
-
MEDORFA
- QTY 30
- 6 %
- EMULSN(G)
- Near 77381
HYDROQUINONE (hahy droh kwi NOHN) treats dark spots on the skin caused by hormones, aging, or sun exposure. It works by decreasing the amount of melanin, a pigment your body makes that gives your skin color. This reduces the appearance of dark spots. Sun prevention measures, including sunscreen, are often combined with this medication. It belongs to a group of medications called skin-lightening agents.
Change Location
Set Price Drop Alert for:
MEDORFA
- QTY 30
- 6 %
- EMULSN(G)
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
MEDORFA
- QTY 30
- 6 %
- EMULSN(G)
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Medicine Chest
MEDORFA Lifestyle Interactions
-
Asciminib 40mg, Oral tablet
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: Do not drink grapefruit juice or eat grapefruit while taking this medication. Grapefruit may alter the effects of your medication. Serious side effects may occur. Contact your care team right away if you experience new or worsening side effects.• Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice during asciminib treatment due to the risk of increased asciminib exposure and adverse reactions. Asciminib is a CYP3A substrate and grapefruit juice is a strong CYP3A inhibitor. -
Asciminib 40mg, Oral tablet
• Interaction: Cannabis• Severity: Major• Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication. Call emergency services right away if you experience slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, or trouble staying awake.• Notes for Professionals: Advise patients to avoid cannabis use during asciminib treatment. Concomitant use may alter the exposure of some cannabinoids and increase the risk for adverse reactions. The cannabinoid delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP2C9 substrates and asciminib is a CYP2C9 inhibitor.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
